Zimmer Biomet

ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer

Retrieved on: 
Wednesday, July 27, 2022
Washington University in St. Louis, Education, University, GLOBE, Insurance, Zimmer Biomet, DTC, U.S. Securities and Exchange Commission, Forward-looking statement, SAN, Stomach, Research, Private Securities Litigation Reform Act, Collection, Marketing, Rehabilitation, Ramakanta Panda, Board, Tensor reshaping, Anatomy, Director, FDA, Interim, Senior, Board of directors, Security (finance), Patient, Nasdaq, Lists of diseases, Annual report, Growth, Risk, Weight loss, Obesity, Management, Pharmaceutical industry

Thomas Stankovich, Chief Financial Officer of ReShape, will serve as Interim President and Chief Executive Officer until Mr. Hickey joins the company.

Key Points: 
  • Thomas Stankovich, Chief Financial Officer of ReShape, will serve as Interim President and Chief Executive Officer until Mr. Hickey joins the company.
  • As we welcome Paul, we also want to express our genuine thanks to Bart for his stewardship of ReShape during his time as President and Chief Executive Officer and wish him the best in his future endeavors.
  • Prior to joining Reshape, since February 2020, Mr. Hickey was the President and Chief Executive Officer of Altimate Medical Holdings, Inc. which designs and manufactures rehabilitation medical equipment including its EasyStand brand.
  • Prior to that, from 2016 to 2017, Mr. Hickey was Senior Vice President of Marketing and Reimbursement for EnteroMedics (now ReShape Lifesciences).

ZimVie to Report Second Quarter 2022 Financial Results on August 10, 2022

Retrieved on: 
Wednesday, July 20, 2022
Life, Webcast, Spine, Solution, GLOBE, Twitter, Zimmer Biomet, Instagram, LinkedIn, Dentistry, Facebook

WESTMINSTER, Colo., July 20, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 10, 2022.

Key Points: 
  • WESTMINSTER, Colo., July 20, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 10, 2022.
  • Company management will host a corresponding audio webcast beginning at 4:30 p.m. Eastern Time.
  • Those interested in listening to the audio webcast should register online here .
  • Participants are encouraged to register more than 15 minutes before the start of the call.

ZimVie Announces Positive Policy Decision from Anthem for Anterior Vertebral Body Tethering, Expanding Coverage to 30+ Million Lives

Retrieved on: 
Tuesday, July 12, 2022
Tether, SEC, Life, Safety, SVP, U.S. Securities and Exchange Commission, Surgeon, BCBS, Solution, HDE, Intention, LinkedIn, Dental, Patient, Instagram, GLOBE, Policy, Scoliosis, Private Securities Litigation Reform Act, Cobb, Motion, Federal, Rocky Mountains, Forward-looking statement, Zimmer Biomet, FDA, Twitter, Spinal fusion, Health insurance, Facebook, Spine, Anthem

This decision marks a significant win for Anthem BCBS patients and the broader pediatric scoliosis community, said Rebecca Whitney, SVP and President of ZimVie Spine.

Key Points: 
  • This decision marks a significant win for Anthem BCBS patients and the broader pediatric scoliosis community, said Rebecca Whitney, SVP and President of ZimVie Spine.
  • The coverage decision from Anthem will provide children with greater access to AVBT as a motion preserving alternative that may allow them to return to their active daily lives.
  • We hope that this decision also paves the way for policy updates from additional payers to positively impact the lives of children with scoliosis.
  • Anthems policy decision can be found here: https://www.anthem.com/dam/medpolicies/abcbs/active/policies/mp_pw_a0535...
    For more information on ZimVie Spine solutions for restorative procedures, please visit https://www.zimvie.com/en/spine.html .

ZimVie Announces Launch of Two Next-Generation Dental Solutions in the United States

Retrieved on: 
Thursday, June 16, 2022
Solution, FDA, Gums, Safety, Efficiency, LinkedIn, GLOBE, Intention, Zimmer Biomet, SVP, Dental, Twitter, Standard of care, Patient, Health, Instagram, Dentist, Breast implant, Element, Torque, Life, Medical device, Dentistry, Facebook, Spine

The T3 PRO is the newest addition to ZimVies family of dental implants and builds on the proven solutions of the T3 Tapered Implant.

Key Points: 
  • The T3 PRO is the newest addition to ZimVies family of dental implants and builds on the proven solutions of the T3 Tapered Implant.
  • ZimVie will begin commercial rollout of these solutions in the United States, with an intention to expand to additional countries pending necessary regulatory approvals.
  • ZimVie is committed to providing innovative treatment options to improve patient care while partnering with dental professionals globally to advance dental technology and end-to-end workflow solutions.
  • For more information on the T3 PRO Tapered Implant and the Encode Emergence, or any of ZimVie Dentals solutions for restorative procedures, please visit https://www.zimvie.com/en/dental.html .

Colson Medical Announces Hjalmar Pompe van Meerdervoort as New Acumed President

Retrieved on: 
Wednesday, June 1, 2022
Osteomed, LLC, Neuro, Marmon, Tool, Iggie Wolfington, CEO, Medicine, Solution, Zimmer Biomet, Health, Growth, Stryker Corporation, Guangzhou, Patient, Berkshire Hathaway, Injury, General manager, Surgeon, CMF, Education, Management, Dentistry, Apex, Acumed

HILLSBORO, Ore., June 1, 2022 /PRNewswire-PRWeb/ -- Colson Medical, LLC announces Hjalmar Pompe van Meerdervoort as President, Acumed, effective June 1. Pompe van Meerdervoort succeeds Sharon Wolfington, who will transition into a new advisory role for Colson Medical, LLC. After nearly five years at Acumed, Wolfington chose to pursue other professional and personal opportunities.

Key Points: 
  • Colson Medical, LLC announces the appointment of Hjalmar Pompe van Meerdervoort to the role of president, Acumed, effective June 1.
  • HILLSBORO, Ore., June 1, 2022 /PRNewswire-PRWeb/ -- Colson Medical, LLC announces Hjalmar Pompe van Meerdervoort as President, Acumed, effective June 1.
  • Pompe van Meerdervoort succeeds Sharon Wolfington, who will transition into a new advisory role for Colson Medical, LLC.
  • Pompe van Meerdervoort brings extensive global healthcare experience with his more than 25-year career in orthopaedics and medical devices.

Centinel Spine Clinical Study for Total Disc Replacement for 2-Level Symptomatic Cervical Disc Disease

Retrieved on: 
Tuesday, May 24, 2022
Sentinel, Intervertebral disc arthroplasty, American Academy of Orthopaedic Surgeons, Anatomy, Effectiveness, Patient, North American Spine Society, Health, Treatment, Clinical trial, Elective surgery, Research, FDA, University, SAN, Zimmer Biomet, CSK, Safety, SK, LLC, Spine, Multicenter Automatic Defibrillator Implantation Trial, Randomized controlled trial, Pharmaceutical industry, Medical device

The prodisc products being used in the trial are built on the prodisc technology platform, the most widely used Total Disc Replacement system in the world.

Key Points: 
  • The prodisc products being used in the trial are built on the prodisc technology platform, the most widely used Total Disc Replacement system in the world.
  • No other disc replacement system has been studied more, with over 13,000 patients reported on in more than 540 articles over a global clinical usage period of over 30 years.
  • Approximately 20 patients will be included in the study at Texas Spine Care Center with a minimum of 390 in the study overall.
  • Centinel Spine derived its name from the "Sentinel Sign", the radiographic confirmation of a successful fusion anterior to the interbody device.

Suketu Upadhyay Elected to Vertex Board of Directors

Retrieved on: 
Wednesday, May 18, 2022
Biotechnology, Pharmaceutical, Genetics, Health, Senior, Business, MBA, Pain, Company, BMS, Endo International, R, International, Suki Kinari Hydropower Project, Duke University, BD, Leadership, AstraZeneca, Cystic fibrosis, Biology, Sickle cell disease, Duchenne muscular dystrophy, Fuqua School of Business, Bristol Myers Squibb, Executive, Duchenne, Research, Becton, Johnson & Johnson, Zimmer Biomet, Albright College, VRTX, Vertex, YouTube, Instagram, Vertex Pharmaceuticals, Fuqua School, CF, LinkedIn, Twitter, Becton, Dickinson and Company headquarters, CFO, Beta thalassemia, Interim, Management, Pharmaceutical industry, List of characters in Ramayana, Science, Facebook, Innovation district

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (Suky) Upadhyay has been elected to its board of directors as an independent director.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (Suky) Upadhyay has been elected to its board of directors as an independent director.
  • We are delighted to have Suky join the Vertex Board.
  • The addition of Mr. Upadhyay brings Vertexs board of directors to 11 members, nine of whom are independent.
  • Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.

Zimmer Biomet Announces Appointment of New Chief Accounting Officer

Retrieved on: 
Monday, May 16, 2022
MBA, ITT Inc., Private Securities Litigation Reform Act, Paul, U.S. Securities and Exchange Commission, Leadership, News, Villanova University, Patient, Solution, Xylem, Health, Xylem Inc., New York University Stern School of Business, Investor relations, NYU, Artificial intelligence, Culture, Intention, FP, Life, Forward-looking statement, Twitter, SEC, Comptroller, Business, NYSE, Controller, Certified Public Accountant, Management, Zimmer Biomet

WARSAW, Ind., May 16, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Paul Stellato as Vice President, Controller and Chief Accounting Officer.  Prior to joining Zimmer Biomet, Mr. Stellato served as Vice President, Finance, Global Business Services at Xylem Inc.

Key Points: 
  • Paul Stellato Joins Zimmer Biomet as Vice President, Controller and Chief Accounting Officer
    WARSAW, Ind., May 16, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Paul Stellato as Vice President, Controller and Chief Accounting Officer.
  • Prior to joining Zimmer Biomet, Mr. Stellato served as Vice President, Finance, Global Business Services at Xylem Inc.
    "With more than two decades of experience and a demonstrated track record of success in all areas of financial services, Paul will be a great addition to our leadership team in his new role," said Suky Upadhyay, Executive Vice President and Chief Financial Officer of Zimmer Biomet.
  • Prior to his most recent role at Xylem Inc., Mr. Stellato served as the company's Vice President, Controller and Chief Accounting Officer and as Vice President Finance, Financial Planning and Analysis.
  • Mr. Stellato spent the early part of his career in public accounting with both Andersen and Ernst & Young.

Zimmer Biomet Debuts First-of-its-Kind Artificial Intelligence Capabilities for Omni™ Suite Intelligent Operating Room

Retrieved on: 
Tuesday, May 10, 2022
Omni, Private Securities Litigation Reform Act, Culture, Twitter, Health, NYSE, Patient, Anesthesia, Connected health, Artificial intelligence, Leadership, Workflow, OR, Hip, Efficiency, Intention, Surgeon, U.S. Securities and Exchange Commission, Life, SEC, Solution, News, AI, Walking, General manager, Medical device, Zimmer Biomet

WARSAW, Ind., May 10, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today introduced the availability of new artificial intelligence¹ (AI) capabilities within Omni™ Suite, an intelligent operating room (OR) designed to optimize surgical workflow and procedural efficiency by automating manual tasks and streamlining unnecessary technology and redundant hardware. The new AI feature uses cameras to automatically recognize and timestamp key OR workflow milestones, including patient entry and exit, door count, the start and stop of anesthesia, surgery and cleaning. Surgical teams are guided through a process to help optimize OR workflow based on real-time access to workflow metrics.

Key Points: 
  • "Omni Suite is more than just another manual integration solution it is a smart system designed to work with OR staff throughout the procedure," said Robert Kraal, Vice President and General Manager, Connected Health at Zimmer Biomet.
  • "Now, with this new feature, surgical teams can utilize and rely on Omni Suite's AI capabilities to optimize OR workflow.
  • "Omni Suite's latest feature further enhances the value and utility of the Omni Suite platform while adding AI capabilities to strengthen our ZBEdge Connected Intelligence Suite," said Ivan Tornos, Chief Operating Officer, Zimmer Biomet.
  • Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.

Syed Jafry Joins Antylia Scientific Board of Directors

Retrieved on: 
Monday, April 25, 2022
Percussion section, Board, EMEA, General Electric, Zimmer Biomet, Water, Executive, Research, Plastic, Life, Science, Board of directors, Cole-Parmer, CAGR, Army Science Board, Goal, GM, GE, Growth, SVP, Thermo Fisher Scientific, Director, TMO, Solution, SRL Diagnostics, Industry, GTCR, Emerging market, Fine chemical, Management, Elective surgery, Spex, Asia-Pacific

VERNON HILLS, Ill., April 25, 2022 /PRNewswire/ -- Antylia Scientific, a global leader of Molecular Diagnostic Reagents and Specialty Chemicals, Water and Air Quality Testing Equipment and Consumables, and Laboratory Products for the pharma, healthcare and environmental markets, announced today that Syed Jafry has joined its Board of Directors. Antylia is a portfolio company of GTCR, a leading private equity firm.

Key Points: 
  • VERNON HILLS, Ill., April 25, 2022 /PRNewswire/ --Antylia Scientific, a global leader of Molecular Diagnostic Reagents and Specialty Chemicals, Water and Air Quality Testing Equipment and Consumables, and Laboratory Products for the pharma, healthcare and environmental markets, announced today that Syed Jafry has joined its Board of Directors.
  • Mr. Jafry also serves on the Board of Directors of Zimmer Biomet, a global leader in orthopedics.
  • "We are excited and honored to have Syed join our Board of Directors," said Bernd Brust, Antylia's Executive Chairman of the Board.
  • Mr. Jafry commented: "I am truly honored to join the Board of Antylia Scientific and to partner with the GTCR team.